Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 843 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Population Mortality from NSCLC in the US Fell Sharply Due to... August 19, 2020 Time to get stratified January 10, 2023 Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... November 10, 2021 Engaging People with Low-Grade Glioma in Cancer Research August 24, 2023 Load more HOT NEWS News digest – Genetic links to male breast cancer, bowel cancer... Ending smoking could more than halve England’s cancer inequality gap Study in India Could Make Immunotherapy More Affordable Worldwide Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than...
